What is William Blair’s Forecast for PTCT Q1 Earnings?

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Research analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of PTC Therapeutics in a research note issued on Friday, February 28th. William Blair analyst S. Corwin expects that the biopharmaceutical company will post earnings per share of ($0.57) for the quarter. The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share. William Blair also issued estimates for PTC Therapeutics’ Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.37) EPS and Q4 2026 earnings at ($0.13) EPS.

Other research analysts also recently issued reports about the company. UBS Group raised their price objective on PTC Therapeutics from $47.00 to $71.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Wells Fargo & Company raised their price objective on PTC Therapeutics from $56.00 to $68.00 and gave the company an “overweight” rating in a research note on Tuesday, November 26th. JPMorgan Chase & Co. cut their price objective on PTC Therapeutics from $74.00 to $72.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. The Goldman Sachs Group raised their price objective on PTC Therapeutics from $32.00 to $42.00 and gave the company a “sell” rating in a research note on Wednesday, December 4th. Finally, Robert W. Baird raised their price objective on PTC Therapeutics from $52.00 to $70.00 and gave the company an “outperform” rating in a research note on Tuesday, December 3rd. Three investment analysts have rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, PTC Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $62.08.

PTC Therapeutics Stock Performance

Shares of PTCT stock opened at $51.80 on Monday. The stock’s 50 day simple moving average is $47.44 and its 200 day simple moving average is $42.59. PTC Therapeutics has a twelve month low of $24.00 and a twelve month high of $55.60. The company has a market capitalization of $4.00 billion, a price-to-earnings ratio of -8.72 and a beta of 0.62.

Institutional Trading of PTC Therapeutics

Several institutional investors have recently bought and sold shares of PTCT. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in PTC Therapeutics in the fourth quarter worth $4,891,000. Mackenzie Financial Corp boosted its stake in PTC Therapeutics by 132.2% in the fourth quarter. Mackenzie Financial Corp now owns 22,776 shares of the biopharmaceutical company’s stock worth $1,028,000 after purchasing an additional 12,967 shares in the last quarter. Toronto Dominion Bank acquired a new position in PTC Therapeutics in the fourth quarter worth $148,363,000. GF Fund Management CO. LTD. acquired a new position in PTC Therapeutics in the fourth quarter worth $73,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in PTC Therapeutics by 19.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 160,251 shares of the biopharmaceutical company’s stock worth $7,234,000 after purchasing an additional 26,274 shares in the last quarter.

Insider Transactions at PTC Therapeutics

In other news, EVP Lee Scott Golden sold 795 shares of PTC Therapeutics stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $50.10, for a total transaction of $39,829.50. Following the sale, the executive vice president now owns 77,856 shares of the company’s stock, valued at approximately $3,900,585.60. This trade represents a 1.01 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Christine Marie Utter sold 879 shares of the business’s stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $50.10, for a total value of $44,037.90. Following the completion of the sale, the chief accounting officer now directly owns 63,442 shares in the company, valued at approximately $3,178,444.20. This represents a 1.37 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 21,640 shares of company stock valued at $1,012,288. 5.50% of the stock is owned by corporate insiders.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.